Ullmann Wealth Partners Group LLC Sells 135 Shares of Johnson & Johnson (NYSE:JNJ)

Ullmann Wealth Partners Group LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,847 shares of the company’s stock after selling 135 shares during the period. Ullmann Wealth Partners Group LLC’s holdings in Johnson & Johnson were worth $709,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Oppenheimer & Co. Inc. boosted its holdings in Johnson & Johnson by 0.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 179,588 shares of the company’s stock valued at $26,249,000 after purchasing an additional 470 shares during the period. Vest Financial LLC boosted its holdings in Johnson & Johnson by 26.2% in the 2nd quarter. Vest Financial LLC now owns 315,493 shares of the company’s stock valued at $46,112,000 after purchasing an additional 65,464 shares during the period. Main Street Financial Solutions LLC boosted its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 36,147 shares of the company’s stock valued at $5,283,000 after purchasing an additional 900 shares during the period. Lansing Street Advisors boosted its holdings in Johnson & Johnson by 3.2% in the 2nd quarter. Lansing Street Advisors now owns 5,506 shares of the company’s stock valued at $805,000 after purchasing an additional 170 shares during the period. Finally, Nelson Capital Management LLC boosted its holdings in Johnson & Johnson by 30.0% in the 2nd quarter. Nelson Capital Management LLC now owns 5,523 shares of the company’s stock valued at $807,000 after purchasing an additional 1,276 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $165.52 on Friday. The company has a 50 day simple moving average of $159.55 and a 200 day simple moving average of $154.04. The stock has a market cap of $398.45 billion, a price-to-earnings ratio of 10.32, a P/E/G ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same period in the prior year, the company earned $2.80 EPS. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.00%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 9th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. The Goldman Sachs Group cut their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.